Endologix Lifts Hold On Shipments Of AAA Devices
The Dec. 29 announcement relating to non-EU shipments of AFX and some AFX2 AAA repair devices came two days after the company said it suspended shipments of its flagship system because a manufacturing issue was causing damage to some devices. The release of the hold allowed the company to end a difficult month on a positive note. Endologix announced the suspension of the CE mark for AFX and AFX2 in Europe earlier in December.
You may also be interested in...
US FDA says that previously identified elevated risks of type III endoleaks from endovascular aneurysm repair systems appears to be linked to a specific, no-longer-sold device, Endogix's AFX with Strata system.
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
The specialist in stent grafts for abdominal aortic aneurysms, Endologix, has suspended shipments of its AFX AAA repair system after discovering that a manufacturing issue was causing damage to some devices. This is the second knock-back the company's biggest seller has had in as many weeks, following a CE-mark suspension earlier this month.